Barinthus Biotherapeutics Plc. ADR (BRNS) saw an uptrend of 39.22% in the recent trading with $1.42 being its most recent. The current price level -10.13% lower than the highest price of $1.58 marked by the stock while trading over the past 52-weeks, whereas it is 121.87% higher than the lowest price of $0.64 the company dropped to over past 52-weeks. The latest news story on BRNS appeared in (ACCESSWIRE) under the title “Barinthus Biotherapeutics’ CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025” on Jun-09-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Barinthus Biotherapeutics Plc. ADR Earnings – What Happened With BRNS
Coming around sales and income figures on BRNS Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Barinthus Biotherapeutics Plc. ADR – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 40.34 million. BRNS does have institutional investors; and they hold 15.32% of the stock.
Key Metrics forBRNS
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Barinthus Biotherapeutics Plc. ADR has a debt to equity ratio of 0.10.
Technical Analysis of Barinthus Biotherapeutics Plc. ADR (NASDAQ:BRNS) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Barinthus Biotherapeutics Plc. ADR (BRNS), we notice that the stock’s 20-day average volume is at 3,509,585 shares and 50% of short term indicators are suggesting the stock as Buy. And to end, BRNS’s 100-day average volume is 726,656 shares with 50% of the long-term indicators pointing towards Buy for the stock.
